WBI Investments Inc. Acquires Shares of 60,188 Organon & Co. (NYSE:OGN)

WBI Investments Inc. acquired a new stake in Organon & Co. (NYSE:OGNFree Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 60,188 shares of the company’s stock, valued at approximately $1,045,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp raised its holdings in shares of Organon & Co. by 27.8% during the 1st quarter. State Street Corp now owns 11,958,385 shares of the company’s stock valued at $417,706,000 after buying an additional 2,599,728 shares during the period. Amundi increased its holdings in Organon & Co. by 98.9% during the 4th quarter. Amundi now owns 3,407,333 shares of the company’s stock worth $104,399,000 after purchasing an additional 1,693,968 shares during the last quarter. Norges Bank purchased a new stake in Organon & Co. during the 4th quarter worth approximately $40,751,000. Goldman Sachs Group Inc. increased its holdings in Organon & Co. by 197.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 2,190,483 shares of the company’s stock worth $45,584,000 after purchasing an additional 1,453,728 shares during the last quarter. Finally, Balyasny Asset Management L.P. increased its holdings in Organon & Co. by 110.3% during the 1st quarter. Balyasny Asset Management L.P. now owns 2,284,191 shares of the company’s stock worth $53,724,000 after purchasing an additional 1,197,979 shares during the last quarter. 77.08% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Price Performance

NYSE:OGN opened at $16.83 on Tuesday. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $29.55. The firm has a market capitalization of $4.30 billion, a P/E ratio of 7.35, a P/E/G ratio of 0.48 and a beta of 0.79. The business has a 50 day simple moving average of $14.90 and a 200 day simple moving average of $16.51.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Piper Sandler dropped their price objective on Organon & Co. from $32.00 to $22.00 and set an “overweight” rating on the stock in a report on Wednesday, November 22nd. The Goldman Sachs Group downgraded Organon & Co. from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $33.00 to $16.00 in a report on Friday, November 3rd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Organon & Co. has a consensus rating of “Moderate Buy” and an average price target of $23.33.

Get Our Latest Research Report on Organon & Co.

Organon & Co. Profile

(Free Report)

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

Recommended Stories

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.